10:42 AM EDT, 04/28/2025 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) , up more than 7% on last look, on Monday said updated clinical data from its ABILITY-1 trial continue to demonstrate its lead candidate MDNA11's effectiveness and safety. The data is being presented at the American Association for Cancer Research meeting in Chicago.

According to a statement, 10 patients achieved an objective response when treated with MDNA11 alone or in combination with Merck's Keytruda. All responders had advanced and/or metastatic cancers with resistance to immune checkpoint inhibitors (ICI) or with historically low responses to ICI.

"We are encouraged by the anti-tumor activity and safety of MDNA11 in both the monotherapy and combination setting, including the 3 recent responders, particularly in patients who have shown resistance to checkpoint inhibitors or with tumor types with historically low responses to immunotherapies and addressing a vastly underserved cancer population," said Fahar Merchant, chief executive. "Today's efficacy and immunodynamic data have provided the foundation to commence the dose expansion portion for MDNA11 in combination with KEYTRUDA. In the monotherapy setting, we continue to see deep and durable single agent activity of MDNA11 with two patients remaining in complete remission and off therapy."

Enrollment in the Phase 2 combination dose expansion arm is underway.

Medicenna was last seen up $0.08, to $1.16, and was even higher on the Toronto Stock Exchange.

Price: 1.16, Change: +0.08, Percent Change: +7.41